BORTEZOMIB IN COMBINATION WITH LOW-DOSE ORAL MELPHALAN, DEXAMETHASONE AND THALIDOMIDE FOR RELAPSED ELDERLY PATIENTS WITH MULTIPLE MYELOMA

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

AZARM TALEB; AKBARI MOJTABA; AZARM AREZOU; MOHAGER HAMID

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: JOURNAL OF RESEARCH IN MEDICAL SCIENCES (JRMS) Year:2011 | Volume:17 | Issue:1 Page(s): 8-14

Download Full-Text

View:

301

Download:

161

Cites:

Information Journal Paper

Title

BORTEZOMIB IN COMBINATION WITH LOW-DOSE ORAL MELPHALAN, DEXAMETHASONE AND THALIDOMIDE FOR RELAPSED ELDERLY PATIENTS WITH MULTIPLE MYELOMA

Author(s)

AZARM TALEB | AKBARI MOJTABA | AZARM AREZOU | MOHAGER HAMID | Issue Writer Certificate

Keywords

MULTIPLE MYELOMA

BORTEZOMIB

DEXAMETHASONE

MELPHALAN

THALIDOMIDE

Abstract

BACKGROUND: The aim of the study was to assess the effects of combination of BORTEZOMIB moderate dose and continuous oral low dose MELPHALAN and THALIDOMIDE and DEXAMETHASONE (BMTD regimen) in elderly patients aged ³65 years with relapsed MULTIPLE MYELOMA (MM).METHODS: Twenty four patients with advanced MM were enrolled to receive eight 3-week treatment cycles with BORTEZOMIB 1.3 mg/m2 on days 1, 4, 8, and 11 followed by three 5-week cycles with BORTEZOMIB 1.3 mg/m2 on days 1, 8, 15, and 22. Within all cycles, DEXAMETHASONE 24 mg/d was given intravenously on the day of BORTEZOMIB injection and the day thereafter. In addition, patients received oral treatment of MELPHALAN at a dose of 5 mg/d continuously for twenty days for every cycle.RESULTS: Mean age of study patients was 72.8±6.4 years. All patients that completed at least one treatment cycle were evaluated for response. Complete, partial, and minor responses occurred in 19%, 65% and 6% of patients, respectively. Overall response rate was 90% (efficacy analysis).CONCLUSIONS: This study demonstrated potent in vivo activity of combination therapy with BMTD regimen in patients with relapsed MM, with an acceptable safety profile and high overall response rate.

Cites

No record.

References

No record.

Cite

APA: Copy

AZARM, TALEB, AKBARI, MOJTABA, AZARM, AREZOU, & MOHAGER, HAMID. (2011). BORTEZOMIB IN COMBINATION WITH LOW-DOSE ORAL MELPHALAN, DEXAMETHASONE AND THALIDOMIDE FOR RELAPSED ELDERLY PATIENTS WITH MULTIPLE MYELOMA. JOURNAL OF RESEARCH IN MEDICAL SCIENCES (JRMS), 17(1), 8-14. SID. https://sid.ir/paper/592122/en

Vancouver: Copy

AZARM TALEB, AKBARI MOJTABA, AZARM AREZOU, MOHAGER HAMID. BORTEZOMIB IN COMBINATION WITH LOW-DOSE ORAL MELPHALAN, DEXAMETHASONE AND THALIDOMIDE FOR RELAPSED ELDERLY PATIENTS WITH MULTIPLE MYELOMA. JOURNAL OF RESEARCH IN MEDICAL SCIENCES (JRMS)[Internet]. 2011;17(1):8-14. Available from: https://sid.ir/paper/592122/en

IEEE: Copy

TALEB AZARM, MOJTABA AKBARI, AREZOU AZARM, and HAMID MOHAGER, “BORTEZOMIB IN COMBINATION WITH LOW-DOSE ORAL MELPHALAN, DEXAMETHASONE AND THALIDOMIDE FOR RELAPSED ELDERLY PATIENTS WITH MULTIPLE MYELOMA,” JOURNAL OF RESEARCH IN MEDICAL SCIENCES (JRMS), vol. 17, no. 1, pp. 8–14, 2011, [Online]. Available: https://sid.ir/paper/592122/en

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops